Sri Lanka to receive USD 500 million concessional financing from South Korea’s Exim Bank
In order to further strengthen the economic cooperation between two countries, the Government of Republic of Korea has agreed to provide concessional loans from the Economic Development Cooperation Fund (EDCF) of the Export Import Bank of Korea (KEximbank), Sri Lanka’s Finance Ministry said.
Accordingly, the Government of Republic of Korea and Government of Sri Lanka have agreed to sign a new Framework Arrangement for the period of 2020-2022 to obtain loans through EDCF up to an aggregate commitment amount of USD 500 million to finance projects mutually agreed.
The loan interest rate on this concessional loan is about as low as 0.15% -0.20% and the loan has a repayment period of about 40 years with a grace period of 10 years, the statement said.
In addition, the two sides agreed to continue the Korean Exim Bank Representative Office, which was opened in Colombo in January 2016 by its Chairman, to further implement the projects in a well-coordinated manner.
The Framework Arrangement was signed today (May 10) by Mr. S R Attygalle, Secretary, Ministry of Finance on behalf of the Government of Sri Lanka, and Mr. Woonjin Jeong, the Ambassador of the Republic of Korea, representing the Republic of Korea.
(Source: Ada Derana)
Latest Headlines in Sri Lanka
- Former CPC Chairman Dhammika Ranatunga granted bail by Colombo Court December 15, 2025
- Sri Lanka condemns Bondi Beach attack in Australia December 15, 2025
- Sri Lanka estimates USD 400 Million for railway reconstruction after Cyclone Ditwah December 15, 2025
- Large-scale drug trafficker arrested in Wattala with 21 kg of cannabis December 15, 2025
- Tragedy at Bondi Beach: Mass shooting at Jewish festival kills 15, injures dozens December 15, 2025
That is welcome news.
The construction of all new Highways like the Ruwanpura Hgwy could be expedited.
We will be able to travel quickly to various towns and villages to pay respect to those who succumb to CV19 Virus and others who succumb to Sinopharma.